Alzheimer’s disease, frontotemporal dementias, progressive supranuclear palsy, Corticobasal degeneration, Clinical Trial Study
< Back to Find a Trial

A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of Frontotemporal Dementia (Alector AL001-2)

ID
NCT03987295
Condition Studied
Frontotemporal Dementia
Phase
Phase II
Status
Closed
Intervention
AL001
Principal Investigator
Sponsor
Alector, Inc.

Please go to ClinicalTrials.gov for more information.